Trials / Sponsors / Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry · 5 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Withdrawn | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-dia Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2015-01-01 |
| Terminated | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-0 Glioblastoma Multiforme | Phase 2 | 2014-10-29 |
| Completed | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation | Phase 1 | 2014-10-23 |
| Completed | A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignanci Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | 2012-12-14 |
| Unknown | A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Solid Tumors | Phase 1 | 2012-02-01 |